Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BHV-7000 by Biohaven for Partial Seizure: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Partial Seizure. According to GlobalData, Phase III...
Troriluzole hydrochloride by Biohaven for Obsessive-Compulsive Disorder: Likelihood of Approval
Troriluzole hydrochloride is under clinical development by Biohaven and currently in Phase III for Obsessive-Compulsive Disorder. According to GlobalData, Phase...
BHV-7000 by Biohaven for Generalized Seizures: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Generalized Seizures. According to GlobalData, Phase III...
BHV-2100 by Biohaven for Migraine: Likelihood of Approval
BHV-2100 is under clinical development by Biohaven and currently in Phase II for Migraine. According to GlobalData, Phase II drugs...
Talditercept alfa by Biohaven for Spinal Muscular Atrophy (SMA): Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to...
BHV-2100 by Biohaven for Neuropathic Pain (Neuralgia): Likelihood of Approval
BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase...
Talditercept alfa by Biohaven for Unspecified Metabolic Disorders: Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase I for Unspecified Metabolic Disorders. According to GlobalData,...
Troriluzole hydrochloride by Biohaven for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Troriluzole hydrochloride is under clinical development by Biohaven and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to...
BHV-7000 by Biohaven for Bipolar I Disorder: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Bipolar I Disorder. According to GlobalData, Phase...
BHV-7000 by Biohaven for Major Depressive Disorder: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Major Depressive Disorder. According to GlobalData, Phase...
Talditercept alfa by Biohaven for Spinal Muscular Atrophy (SMA): Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to...
BHV-1300 by Biohaven for Rheumatoid Arthritis: Likelihood of Approval
BHV-1300 is under clinical development by Biohaven and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I...
Noraramtide by Biohaven for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Noraramtide is under clinical development by Biohaven and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData,...
GQ-1010 by Biohaven for Epithelial Tumor: Likelihood of Approval
GQ-1010 is under clinical development by Biohaven and currently in Phase II for Epithelial Tumor. According to GlobalData, Phase II...
Troriluzole hydrochloride by Biohaven for Gliosarcoma: Likelihood of Approval
Troriluzole hydrochloride is under clinical development by Biohaven and currently in Phase III for Gliosarcoma. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Biohaven's BHV-1300?
BHV-1300 is a small molecule commercialized by Biohaven, with a leading Phase I program in Rheumatoid Arthritis. According to Globaldata,...